Hyperthyroidism / Thyrotoxicosis Pharmacotherapy

3,079 views 30 slides Apr 04, 2020
Slide 1
Slide 1 of 30
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8
Slide 9
9
Slide 10
10
Slide 11
11
Slide 12
12
Slide 13
13
Slide 14
14
Slide 15
15
Slide 16
16
Slide 17
17
Slide 18
18
Slide 19
19
Slide 20
20
Slide 21
21
Slide 22
22
Slide 23
23
Slide 24
24
Slide 25
25
Slide 26
26
Slide 27
27
Slide 28
28
Slide 29
29
Slide 30
30

About This Presentation

Thyrotoxicosis is any syndrome caused by excess thyroid hormone and
can be related to excess hormone production (hyperthyroidism).It is Also called as overactive thyroid.Symptoms include unexpected weight loss, rapid or irregular heartbeat, sweating and irritability, although the elderly often exper...


Slide Content

Hyperthyroidism Dr. Chavan P. R. Pharm D

D EFINITION Thyrotoxicosis is any syndrome caused by excess thyroid hormone and can be related to excess hormone production (hyperthyroidism).

Etiology

PATHOPHYSIOLOGY

CLINICAL PRESENTATION

DIAGNOSIS

Thyroid level chart

DESIRED OUTCOME To normalize the production of thyroid hormone Minimize symptoms and long-term consequences Provide individualized therapy based on the type and severity of disease, patient age and gender, existence of nonthyroidal conditions, and response to previous therapy

NONPHARMACOLOGIC THERAPY Surgical removal of the thyroid gland should be considered in patients with a large gland (>80 g), severe ophthalmopathy , or a lack of remission on antithyroid drug treatment . If thyroidectomy is planned, propylthiouracil (PTU) or methimazole (MMI) is usually given until the patient is biochemically euthyroid (usually 6 to 8 weeks), followed by the addition of iodides (500 mg/day) for 10 to 14 days before surgery to decrease the vascularity of the gland. Levothyroxine may be added to maintain the euthyroid state while the thionamides are continued. Complication of surgery: 1.Hypothyroidism, 2.Recurrent laryngeal nerve injury, 3.Airway obstruction, 4.Wound infection.

Treatment

Mechanisms of antithyroid drugs

Thioureas ( Thionamides ) o Propylthiouracil (PTU) and Methimazole * Mechanism of action PTU and methimazole block thyroid hormone synthesis by inhibiting the peroxidase enzyme system of the thyroid, preventing oxidation of trapped iodide and by inhibiting coupling of MIT and DIT to form T4 and T3. PTU (but not methimazole ) also inhibits peripheral conversion of T4 to T3. * Initial dose Usual initial doses include PTU300 to 600 mg daily (usually in three or four divided doses) or methimazole 30 to 60 mgdaily given in three divided doses. Evidence exists that both drugs can be given as a single daily dose.

*Maintenance dose Typical daily maintenance doses are PTU 50 to 300 mg and methimazole 5 to 30 mg. Continue therapy for 12 to 24 months to induce long-term remission. Improvement in symptoms and laboratory abnormalities should occur within 4 to 8 weeks, at which time a tapering regimen to maintenance doses can be started . * Monitoring Monitor patients every 6 to 12 months after remission.

Adverse effects Agranulocytosis (with fever, malaise, gingivitis, or pharyngeal infection, Aplastic anemia, Lupus-like syndrome, Polymyositis , GI intolerance, Hepatotoxicity , Hypoprothrombinemia Pruritic maculopapular rashes, Arthralgias , fever, and Benign transient leukopenia (white blood cell count

Iodides * Mechanism of action Acutely blocks thyroid hormone release, inhibit thyroid hormone biosynthesis by interfering with intrathyroidal iodide use, and decreases size and vascularity of the gland. * Dosage form Potassium iodide is available as a saturated solution (SSKI, 38 mg iodide per drop) or as Lugol`s solution, containing 6.3 mg of iodide per drop . * Dose Typical starting dose of SSKI is 3 to 10 drops daily (120–400 mg) in water or juice. Whenused to prepare a patient for surgery, it should be administered 7 to 14 days preoperatively. Symptom improve occur within 2-7 days of initial therapy

Adverse effects Hypersensitivity reactions (skin rashes, drug fever, rhinitis, conjunctivitis), Salivary gland swelling, “ iodism ” (metallic taste, burning mouth and throat, sore teeth and gums, symptomsof a head cold, and sometimes stomach upset and diarrhea), and Gynecomastia .

Adrenergic Blockers o Propranolol and Nadolol *β-Blockers are used to ameliorate thyrotoxic symptoms such as palpitations, anxiety, tremor, and heat intolerance, they have no effect on peripheral thyrotoxicosis or prevent thyroid storm . * β-Blockers are usually used as adjunctive therapy with antithyroid drugs and RAI or iodide. The only conditions for which β-blockers are primary therapy for thyrotoxicosis are those associated with thyroiditis . * Initial Dose Propranolol dose 20 to 40 mg orally four times daily is effective for most patients (heart rate

Contraindications 1.Decompensated heart failure 2.Sinus bradycardia . 3.Concomitant therapy with monoamine oxidase inhibitors or tricyclic antidepressants. 4.Patients with spontaneous hypoglycemia. Centrally acting sympatholytic ( eg , clonidine ) and calcium channel antagonists ( eg , diltiazem ) may be useful for symptom control when contraindications to β- blockade exist.

Adverse effects Nausea, Vomiting, Anxiety, Insomnia, Lightheadedness, Bradycardia , and Hematologic disturbances.

Radioactive Iodine * Mechanism Sodium iodide–131 is an oral liquid that concentrates in the thyroid and initially disrupts hormone synthesis by incorporating into thyroid hormones and thyroglobulin . *Uses: Agent of choice for Graves’ disease, toxic autonomous nodules, and toxic multinodular goiters.

*Dose : The goal of therapy is to destroy overactive thyroid cells, and a single dose of 4000 to 8000 rad (40–80 Gy ) results in a euthyroid state in 60% of patients at 6 months or sooner. A second dose of RAI should be given 6 months after the first RAI treatment if the patient remains hyperthyroid. Patients with cardiac disease and elderly patients are often treated with thionamides prior to RAI ablation because thyroid hormone levels transiently increase after RAI treatment due to release of preformed thyroid hormone. Antithyroid drugs are not routinely used after RAI because their use is associated with a higher incidence of posttreatment recurrence or persistent hyperthyroidism. If iodides are administered, they should be given 3 to 7 days after RAI to prevent interference with uptake of RAI in the thyroid gland.

* Adverse effects: Hypothyroidism commonly occurs months to years after RAI. The acute, shortterm side effects include mild thyroidal tenderness and dysphagia . * Contraindication: Pregnancy is an absolute contraindication to use of RAI.

Treatment of Thyroid Storm Initiate the following therapeutic measures promptly: Suppression of thyroid hormone formation and secretion. Antiadrenergic therapy. Administration of corticosteroids. Treatment of associated complications or coexisting factors that may have precipitated the storm.

Iodides, which rapidly block the release of preformed thyroid hormone, should be administered after a thionamide is initiated to inhibit iodide utilization by the overactive gland. Antiadrenergic therapy with the short-acting agent esmolol is preferred because it can be used in patients with pulmonary disease or at risk for cardiac failure and because its effects can be rapidly reversed. Corticosteroids are generally recommended, but there is no convincing evidence of adrenocortical insufficiency in thyroid storm; their benefits may be attributed to their antipyretic action and stabilization of blood pressure (BP). General supportive measures, including acetaminophen as an antipyretic (avoid aspirin or other nonsteroidal anti-inflammatory drugs, which may displace bound thyroid hormone), fluid and electrolyte replacement, sedatives, digoxin , antiarrhythmics , insulin, and antibiotics should be given as indicated.

PREGNANCY PTU is considered the drug of choice during the first trimester of pregnancy To prevent fetal goiter and suppression of fetal thyroid function, PTU is usually prescribed in daily doses of 300 mg or less and tapered to 50 to 150 mg daily after 4 to 6 weeks. PTU doses of less than 200 mg daily are unlikely to produce fetal goiter. During the second and third trimesters, MMI is thought to be the drug of choice because of the greater risk of hepatotoxicity with PTU.

Neonatal and Pediatric Hyperthyroidism The disease is usually expressed 7 to 10 days postpartum and treatment with antithyroid drugs (PTU 5 to 10 mg/kg/day or MMI 0.5 to 1 mg/kg/day) may be needed for as long as 8 to 12 weeks until the antibody is cleared . Iodide (potassium iodide one drop per day or Lugol’s solution one to three drops per day) and sodium iodate may be used for the first few days to acutely inhibit hormone release. Childhood hyperthyroidism has classically been managed with either PTU or MMI.

EVALUATION OF THERAPEUTIC OUTCOMES Evaluation on a monthly basis until patient reach a euthyroid condition. Note of Clinical signs of continuing thyrotoxicosis or the development of hypothyroidism After t4 replacement is initiated, the goal is to maintain both the free t4 level and the TSH concentration in the normal range. Once a stable dose of t4 is identified, the patient may be followed every 6 to 12 months.

Thank you